Clinical research on radiotherapy treatment

Addenbrooke’s Hospital houses one of the top-rated radiotherapy services in the UK. The national agenda is to improve access to Intensity Modulated Radiation Treatment (IMRT). This ability to shape radiation dose precisely to the tumour target means that the amount of radiation received by critical organs and normal tissues surrounding the tumour can be reduced or avoided. This reduces the toxic side-effects of radiotherapy and means that higher radiation doses can be given. The Hospital treats 30% of patients with IMRT, compared to the national average of 13%.

Computational radiotherapy
Radiotherapists, physicists and engineers are working together to try and improve treatment for cancer patients. VoxTox is a project that tests computer programs that track how organs move between radiotherapy sessions to minimise any possible damage to healthy tissue. Research shows that organs, such as the prostate, can move by up to 2 cm between radiotherapy sessions, and the resulting damage to surrounding healthy tissues can have lasting effects. The new software (used by the Cavendish Laboratory as part of their work with CERN) will help limit this by providing a clearer picture of exactly how much radiation is hitting the healthy tissues.

Current open trials in Cambridge

The table below lists the current open trials in radiotherapy cancer treatment coordinated by the Cambridge Cancer Trials Centre (last updated 13 July 2016).

Trial name Trial description Contact
ENZARAD Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer Dr Yvonne Rimmer
FAST-Forward Lymph nodes

Randomised clinical trial testing a 1-week course of curative whole breast radiotherapy against a standard 3-week schedule in terms of local cancer control and late adverse effects in patients with early breast cancer. The lymph node arm of this trial is applicable to patients who have an additional requirement for lymphatic Radiotherapy

Dr Charlotte Coles

A multicentre randomised phase II study of
HYpofractionated Bladder Radiotherapy with or without Image guided aDaptive planning

Dr Yvonne Rimmer

A phase II study of intensity modulated radiotherapy (IMRT) in primary bone and soft tissue sarcoma.
A prospective multicentre phase II trial with three separately analysed cohorts:
Cohort 1: Limb/limb girdle soft tissue sarcoma (STS) receiving (neo)-adjuvant radiotherapy (RT)
Cohort 2: Patients with Ewing’s sarcoma of the spine/pelvis receiving definitive radical or (neo)-adjuvant RT
Cohort 3: Patients with non-Ewing’s primary bone sarcomas of the spine/pelvis receiving definitive radical or adjuvant RT

Dr Gail Horan
Neo-AEGIS Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (Modified MAGIC regimen) vs. neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the oesophagus and oesophago-gastric junction Dr David Gilligan
NIMRAD A randomised placebo-controlled trial of synchronous NIMorazole versus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemotherapy or cetuximab Dr Richard Benson

International randomised study of laparoscopic prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for early stage organ-confined prostate cancer. (currently only open for study B)
In PACE B: Nonsurgical candidates or patients who decline surgery will be randomised to either prostate SBRT (36.25 Gy in 5 fractions) or conventional radiotherapy (investigators choice between 78 Gy in 39 fractions or 62 Gy in 20 fractions

Dr Alex Martin
QuaRTUS A study investigating the feasibility of using ultrasound elastography to more accurately assess the effects of breast radiotherapy Dr Charlotte Coles
RAIDER A Randomised phase II trial of Adaptive Image guided standard or Dose Escalated tumour boost Radiotherapy in the treatment of transitional cell carcinoma of the bladder Dr Yvonne Rimmer
RAPPER Radiogenomics: assessment of polymorphisms for predicting the effects of radiotherapy Prof Neil Burnet
SCALOP-2 A multi‐centre randomised study of induction chemotherapy followed by capecitabine (+/‐nelfinavir) with high or standard dose radiotherapy for locally advanced non‐metastatic pancreatic cancer Dr Thankamma Ajithkumar
VoxTox An observational study to collect comprehensive toxicity data and optimized image data for patients undergoing image guided intensity-modulated radiotherapy for cancers of the head and neck region or the prostate or tumours of central nervous system. These three site specific tumour sites will each be divided into two sub section; discovery (having had radiotherapy treatment up to 4 years ago) and consolidation (due to have radiotherapy treatment and to follow up for a 5 year period there after). The participant will therefore fit into one of the following non randomised arms: Discovery prostate; Consolidation prostate; Discovery head and neck; Consolidation head and neck; Discovery CNS; Consolidation CNS;  Prof Neil Burnet

If you would like further information about how to take part in any of the clinical trials listed here, please talk to your cancer specialist as patients usually need to be referred by their doctor.

Cambridge Cancer Trials Centre (CCTC) contact for radiotherapy trials:  +44(0) 1223 216083 (CCTC general office)